APA (7th ed.) Citation

T, I., Y, U., H, S., M, K., T, S., K, Y., . . . H, M. (2026). Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: A multicenter prospective cohort study. Breast cancer research : BCR. https://doi.org/10.1186/s13058-026-02313-9

Chicago Style (17th ed.) Citation

T, Ishikawa, et al. "Real-world Data for a CDK4/6 Inhibitor, Palbociclib, as 1st- or 2nd-line Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Prospective Cohort Study." Breast Cancer Research : BCR 2026. https://doi.org/10.1186/s13058-026-02313-9.

MLA (9th ed.) Citation

T, Ishikawa, et al. "Real-world Data for a CDK4/6 Inhibitor, Palbociclib, as 1st- or 2nd-line Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Prospective Cohort Study." Breast Cancer Research : BCR, 2026, https://doi.org/10.1186/s13058-026-02313-9.